A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study.
Russell ScottJerry MorganZachary ZimmerRaymond L H LamEdward A O'NeillKeith D KaufmanSamuel S EngelAnnaswamy RajiPublished in: Diabetes, obesity & metabolism (2018)
In patients with type 2 diabetes, mild renal insufficiency and inadequate glycaemic control on metformin ± sulfonylurea, sitagliptin treatment resulted in greater improvement in glycaemic control compared with dapagliflozin and was generally well tolerated.
Keyphrases